2026 Q2 Portfolio Activity
In 2026 Q2, BIOS Capital Management, LP maintained a portfolio of 6 distinct positions. They heavily accumulated shares in REIN THERAPEUTICS INC, increasing the position by 50.4%. The fund also reduced its exposure to LANTERN PHARMA INC by 71.1%.
Position History
hover any row below to update
Loading…
Total Positions
6
Quarter
2026 Q2
Top Holding
ACTU (36.9%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-6 of 6
BIOS Capital Management, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ACTU
ACTUATE THERAPE...
|
Healthcare | 36.90% | 52.09% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
10,049,996 | $15,376,494 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 36.33% | 31.70% |
#2
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
3,683,429 | $15,138,893 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CGTX
COGNITION THERA...
|
Healthcare | 16.56% | 8.63% |
#3
Prev: #3
|
6.0 |
—
|
no change | no change |
P
S
|
6,000,000 | $6,900,001 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RNTX
REIN THERAPEUTI...
|
Healthcare | 7.44% | 4.87% |
#4
Prev: #4
|
6.5 |
—
|
1,000,000 | 50.4% |
P
S
|
2,982,375 | $3,101,670 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LTRN
LANTERN PHARMA ...
|
Healthcare | 2.50% | 2.24% |
#5
Prev: #5
|
1.5 |
—
|
-615,038 | -71.1% |
P
S
|
249,397 | $1,039,985 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
INAB
IN8BIO INC
|
Healthcare | 0.27% | 0.47% |
#6
Prev: #6
|
0.1 |
—
|
-86,848 | -51.8% |
P
S
|
80,957 | $114,149 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-6 of 6 holdings